1001547-71-2

Upstream product

• 501-53-1 benzyl chloroformate 
• 1001548-20-4 (S)-2-amino-1-[(S)-2,5-dihydrofuran-2-yl]ethanol 
• 1001548-21-5 (R)-2-amino-1-[(S)-2,5-dihydrofuran-2-yl]ethanol 
• 54522-28-0 (3R,3aS,6R,6aS)-hexahydrofuro[3,2-b]furan-3,6-diyl bis(4-methylbenzenesulfonate) 
• 72631-59-5 (3R,3aS,6R,6aR)-6-hydroxy-3-(4-methoxyphenyl)sulfonyloxyperhydrofuro[3,2-b]furan 
• 1001547-69-8 (3R,3aS,6S,6aS)-6-bromohexahydrofuro[3,2-b]furan-3-yl 4-methylbenzenesulfonate 
• 1001547-70-1 (R)-1-((S)-2,5-dihydrofuran-2-yl)-2-hydroxyethyl 4-methyl-benzenesulfonate 

Downstream Products

• 1001547-77-8 (S)-2-(benzyloxycarbonylamino)-1-((S)-2,5-dihydrofuran-2-yl)ethyl 4-methylbenzenesulfonate 
• 1001660-41-8 benzyl (S)-2-tert-butoxy-2-((S)-2,5-dihydrofuran-2-yl)ethyl carbamate 
• 1001660-55-4 benzyl (S)-2-((S)-2,5-dihydrofuran-2-yl)-2-methoxyethyl carbamate 
• 1001548-23-7 (3R,3aR,6S,6aS)-3-hydroxyhexahydro-2H-furo[3,2-b]pyrrol-6-yl 4-methylbenzenesulfonate 
• 1001660-36-1 C₂₁H₂₃NO₇S 
• 1172140-58-7 C₁₃H₁₇NO₂ 
• 1172140-59-8 (3aS,6S,6aR)-(9H-fluoren-9-yl)methyl 6-benzyl-3-oxotetrahydro-2H-furo[3.2-b]pyrrole-4(5H)-carboxylate 
• 1172140-57-6 (3R,3aR,6S,6aR)-(9H-fluoren-9-yl)methyl 6-benzyl-3-hydroxytetrahydro-2H-furo[3.2-b]pyrrole-4(5H)-carboxylate 

Relevant academic research and scientific papers

TETRAHYDROFURO [3, 2-B] PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEASES

A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, wherein one of R1 and R2 is H, and the other is selected fromC1-8-alkyl, C3-6-cycloalkyl and C1-8/sub

TETRAHYDROFURO [3, 2-B] PYRR0L-3-ONES AS CATHEPSIN K INHIBITORS

The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein: X is CH or N; one of R1 and R2 is H, and the other is selected from H, OR6, SR6, NR6R

TETRAHYDROFURO (3, 2-B) PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES

Compounds of formula (I) and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget' s disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage

TETRAHYDROFURO [3, 2 -B] PYRR0L-3-ONES AS CATHEPSIN K INHIBITORS

The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein: X is CH or N; one of R1 and R2 is H, and the other is selected from from OR6, SR6, NR6/sup

TETRAHYDROFURO [3, 2-B] PYRR0L-3-0NE INTERMEDIATES

The present invention relates to a process for preparing a compound of formula (Ia), (Ib), (Ic) or (Id), or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof, said process comprising the steps of: (A) (i) treating a compound

FURO [3,2-B] PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS

The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof (I), wherein: one of R1 and R2 is H, and the other is selected from F and Cl, or R1 and R2 are both F; R3 is selected from cyclopentyl and cyclohexyl; R4 is an optionally substituted 5- or 6-membered monocyclic or an 8- to 10-membered bicyclic aryl or heteroaryl ring which includes up to four heteroatoms. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as bone metastases and associated pain.